May 14, 2020
FDA accelerates development of COVID-19 prevention, treatment options
Editor's Note
The Food & Drug Administration on May 11 took new actions to accelerate the development of novel prevention and treatment options for COVID-19.
The agency is providing guidance documents to make the process for submitting applications to initiate studies for new drugs and biological products more efficient.
The documents also outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these products for COVID-19.
Free Daily News
- Study: Excessive nurse overtime, agency staffing harm patients
- Commentary: Technology no substitute for cadaver-based medical education
- Study: Early-stage breast cancer surgery may not be necessary after chemo, radiation
- Experimental brain implant translates thoughts to speech
- Nurses deem flexible, transparent scheduling key to satisfaction, retention
- OR Manager 2025 Career/Salary Survey offers opportunities to learn, give back
- The Joint Commission revises volume criteria for cardiac, stroke certifications
- Pulse oximetry monitoring at home found to save lives of high-risk opioid surgery patients
- New data suggest same-day discharge is safe for joint replacement patients with atrial fibrillation
- FBI investigates as Oracle health data breach exposes patient information
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement